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ABSTRACT 
Ceramide is a family of closely related molecules, which are presumed to be in the center of 
sphingolipid metabolism. Among sphingolipid metabolites, several ceramide subspecies and 
sphingosine induce apoptosis, cell cycle arrest and death, whereas sphingosine 1-phosphate 
(S1P) mediates cell proliferation, invasion, angiogenesis and metastasis. Cell fate is largely 
dependent on the balance of ceramide and sphingosine versus S1P. The sphingosine kinases 
(SKs) are responsible for maintaining this balance, which leans towards S1P in many cancers. 
Thereby SKs have been suggested as targets for cancer therapy. The overall aim of this thesis 
was to target SKs in order to enhance the effects of anti-cancer agents in hepatocellular 
carcinoma (HCC) and bladder cancer cells. 
In study I, we have treated HCC cell lines with selenite in combination with pharmacological 
inhibitors of sphingolipid-metabolizing enzymes. Selenite treatment induced the activity of 
neutral sphingomyelinase and increased the levels of long chain ceramides. Moreover, the 
sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI-II) 
sensitized HCC cells to selenite treatment by increasing the levels of ceramide subspecies, 
inducing reactive oxygen species formation and apoptosis, and inhibiting cell cycle 
progression and cell viability. 
In study II, HCC cell lines were co-treated with the multi-tyrosine kinase inhibitor sorafenib 
and the sphingosine agonist FTY720 in order to improve the efficacy of sorafenib treatment. 
We have shown that a marginally toxic dose of FTY720 synergistically increased the 
cytotoxicity of sorafenib towards the Huh7 and HepG2 cell lines. Combined treatment with 
FTY720 and sorafenib mediated cell cycle arrest, caspase-dependent and –independent 
apoptosis, autophagy blockage and cell death in Huh7 cells. 
In study III, the treatment effects of supernatant from Bacillus Calmette-Guérin -activated 
macrophages (SupBCG) and SKI-II on murine bladder cancer cell lines were studied. 
Combined treatment with SKI-II and SupBCG mediated a decrease in cell viability compared 
to SupBCG treatment alone. There was a transient increase in Sphk1 mRNA level following 
SupBCG treatment, but the SK1 protein level was unaffected. SupBCG and SKI-II 
individually induced PARP-cleavage. The level of dihydro C16-ceramide was increased 
following SKI-II treatment alone, and was further enhanced after combined treatment with 
SupBCG.  
In our studies we have observed that inhibition of SKs enhanced the cytotoxicity of treatment 
with selenite or sorafenib in HCC cell lines, and of BCG in bladder cancer cell lines. 
Therefore, we conclude that targeting these enzymes could potentiate other treatment effects 
in HCC and bladder cancer cells.  
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1 INTRODUCTION 
1.1 SPHINGOLIPIDS  
Sphingolipids were named after the Greek mythological creature ‘Sphinx’ because of their 
enigmatic nature. They were first described by the neurochemist J. L. W. Thudicum in 1880s 
when he discovered and named ‘sphingosine’ meaning ‘bind tight’ as a compound of brain 
lipids [1, 2]. Sphingolipids, e.g. ceramides, sphingosine, sphingomyelins (SM), sulfatides and 
gangliosides, are compounds that possess a long chain amino alcohol backbone and free-fatty 
bases. Sphingolipids are ubiquitous; they constitute about 30% of the total lipid of the plasma 
membranes. Sphingomyelin and glycosphingolipids (GLSs) are the major sphingolipids in 
the eukaryotic biological membranes and contribute to the regulation of membrane fluidity 
and sub-domain structure, and cell–cell contact. Various intermediates of the sphingolipid 
metabolism e.g. sphingosine, sphingosine 1-phosphate (S1P), ceramide (Cer) and ceramide 1-
phosphate (C1P) function as intra-or extracellular messengers. Sphingolipids play vital roles 
in development, cell growth, adhesion, death, migration, senescence, immune cell trafficking, 
behavior of proteins and receptors and vascular and endothelial integrity. They are crucial 
regulators in normal physiology as well as in inflammatory diseases and cancer [2-8]. 
 
Figure 1 Structure of C18- ceramide 
Image collected from National Center for Biotechnology Information, PubChem Compound Database [9]. 
1.1.1 Sphingolipid metabolism  
The central metabolite of sphingolipid metabolism is considered to be ceramide. Ceramide is 
a class of molecules rather than a single molecule, which serves as the structural and 
metabolic precursor for complex sphingolipids and contains amide-linked acyl chains of 
different lengths [6] Fig 1. More than 200 subspecies of mammalian ceramides are the result 
of combinatorial synthesis from collaboration of several enzymes [10]. Ceramides of 
different chain lengths may have opposing effects in different tissues [11]. They can be 
synthesized de novo in the endoplasmic reticulum by the condensation of serine and 
palmitoyl-Co A by the action of serine palmitoyltransferase, followed by the sequential act of 
3-ketodihydrosphingosine reductase, (dihydro) ceramide synthases (CerS) and 
dihydroceramide desaturase (Des) (Fig 2) [12]. Six different CerS (CerS1-6) were identified 
in mammals. CerS have different tissue- and substrate specificity; substrate specificity is 
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largely dependent on acyl-CoA chain lengths, which leads to the generation of various chain 
length ceramides. They show a number of overlapping substrate specificities, e.g. CerS1 can 
produce C18/ C20-Cer; CerS2 produces C20- to C26-Cer; CerS3 produces C18- to C32-Cer; 
CerS4 produces C18/ C20-Cer; CerS5 produces C16-Cer; and CerS6 produces C14/ C16/ 
C18-Cer [13-15]. The last step of the de novo ceramide synthesis pathway is the oxidation of 
dihydroceramide (dhCer) to ceramide by dihydroceramide desaturase 1 [16]. Physiological 
and pathological functions of ceramide are well known but it was believed for a long time 
that dhCer species are physiologically inactive. In recent years it was shown that dhCer 
accumulated following treatment with fenretinide, resveratrol, curcumin, celecoxib, and 
following hypoxia. Chemical and genetic suppression of Des led to dhCer accumulation, 
which led to apoptosis, cell cycle arrest, and autophagy [16-18]. Ceramides may have tumor 
promoting or suppressing effects depending on their fatty acid chain lengths; e.g. in head and 
neck squamous cell carcinoma C16- ceramide induced tumor growth whereas C18- ceramide 
inhibited tumor growth [11, 19]. The de novo pathway can be activated by heat shock [20], 
chemotherapeutic agents [21], and cannabinoids [22]. Ceramide can also be formed in the 
endo/ lyso-some by the hydrolysis of sphingomyelin by the action of either acid or neutral 
sphingomyelinases (SMases) [23]. In vitro this pathway of ceramide generation can be 
activated by treatment with TNF- α, Fas ligands or oxidative stress [24]. The third way of 
ceramide generation, which is called salvage pathway or sphingolipid-recycling pathway is 
more complex and exploits a variety of enzymes. In the plasma membrane and lysosomes 
complex sphingolipids are broken down into sphingosine, which can be recycled back by 
CerS to ceramide [25]. Possible enzymes taking part in this pathway are ceramidases, dihydro 
ceramide synthases and SMases. Selection of the pathway activation to generate ceramide 
might be dependent on different stimuli [25]. Ceramides have many biological functions 
including apoptosis [26], cellular trafficking and growth arrest [25].   
Ceramides can be glycosylated by glucosylceramide synthase (GCS) to produce 
glucosylceramide, which is linked to multi-drug resistance or deacylated by ceramidase to 
form sphingosine, which has tumor suppressive effects by inducing cell cycle arrest and 
apoptosis [27]. Metabolism of ceramide to sphingomyelin and to the majority of complex 
glycosphingolipids occurs in the golgi. Transportation of ceramide from endoplasmic 
reticulum (ER) to golgi is mediated by the ceramide transfer (CerT) protein during 
sphingomyelin synthesis and by vesicular transportation during glycospingolipid synthesis 
[2]. Sphingosine can further be phosphorylated to S1P by the catalytic activity of sphingosine 
kinases. S1P promotes angiogenesis, cancer cell proliferation and metastasis [28]. Another 
complex sphingolipid galactosylceramide can be synthesized by the enzyme ceramide 
galactosyltransferase (CGT), which exploits UDP-galactose and ceramide in the process. 
CGT has limited tissue distribution (e.g. oligodendrocytes, kidneys, intestines and testis), and 
galactosylceramide is the precursor of sulfatides which are extremely important for the 
function of oligodendrocytes e.g. for myelination. Ceramides can also be phosphorylated in 
the trans-golgi and possibly in the plasma membrane to produce ceramide 1-phosphate by 
ceramide kinase (CK). CK has higher specificity towards ceramides containing acyl chains 
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longer than 12 carbons. In the golgi, C1P can function as a docking site for cytosolic 
phospholipase A2, and there by facilitates release of arachidonic acid [6]. Sphingolipids have 
rapid turnover and their levels are maintained by the balance between synthesis and 
degradation in different compartments [10]. 
 
Figure 2 Sphingolipid metabolism pathways 
Sphingolipids are inter-convertible and ceramide is considered to be the central molecule of sphingolipid 
metabolism. It can be synthesized de novo by the condensation of serine and palmitoyl CoA or from the 
hydrolysis of sphingomyelin or cerebrosides (Glucosylceramide, Galactosylceramide). Ceramide can be further 
phosphorylated to ceramide-1-phosphate by ceramide kinase or can serve as a substrate for the synthesis of 
glycolipids and sphingomyelin. Ceramide can be metabolized to sphingosine by ceramidases, and sphingosine in 
turn can be phosphorylated to produce S1P by the action of sphingosine kinases. S1P can be cleaved to 
ethanolamine 1- phosphate and C16-fatty aldehyde by S1P lyase and to exit from the sphingolipid pathway. SPT– 
Serine palmitoyl transferase; KDSR– 3-keto dihydro sphinganine reductasse; dhCerS1-6– dihydro ceramide 
synthase 1-6; Des– dihydroceramide desaturase; CerS– Ceramide synthase; CDase– Ceramidase; SK– 
Sphingosine kinase; S1PP– Sphingosine -1- phosphate phosphatase; S1PL– S1P lyase; CGT– Ceramide 
galactosyl transferase; GALCDase– Galactosyl ceramidase; GALST– Galactosylceramide sulfotransferase; 
SMS– sphingomyelin synthase; SMase– Sphingomyelinase; C1PP– C1P phosphatase; CK– Cearmide kinase; 
GCase– Glucosyl ceramidase; GCS– Glucosyl ceramide synthase. 
1.1.2 Sphingosine kinases 
Sphingosine kinases are evolutionary conserved enzymes and are expressed in humans, mice, 
yeast, plants, worms and flies. They are located mainly in the cytosol but can translocate to 
the biological membranes upon phosphorylation. Two distinct isoforms of sphingosine 
kinases were isolated and characterized in mammals that are SK1 and SK2 [29, 30].  These 
two iso-enzymes can have compensatory, overlapping or different functions depending on 
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cell or tissue expression. Knocking out of either of them in mice does not affect development 
or survival. However, double knock out is embryonic lethal due to lack of S1P [31, 32]. The 
enzymes arise from the Sphk1 and Sphk2 genes, each generating a number of splice variants. 
Both of the SKs possess very similar amino acid sequences and five evolutionarily conserved 
domains. SK2 differs from SK1 in its amino terminus and central region, where SK2 
possesses a proline-rich polypeptide insert [29, 30, 33]. Their size, cellular localization, 
expression and catalytic properties vary from each other. The chromosomal locations of 
human SK1 and SK2 are 17q25.2 and 19q13.1 respectively. They share similarities with large 
diacylglycerol (DAG) kinase family regarding their catalytic domain and diverse structure 
and tissue distribution [29, 30]. Sphingosine kinases phosphorylate non-polar sphingosine to 
polar S1P. The level of S1P is tightly regulated inside and outside of the cell by controlling its 
synthesis mediated by SKs, its irreversible conversion to ethanolamide by S1P lyase and its 
reversible dephosphorylation to sphingosine by S1P phosphatase. The biological activities of 
SKs seem to be keeping the balance between their substrate sphingosine and product S1P. 
S1P is a bioactive polar lipid that is a ligand to S1P receptors (S1PR1-5), which are members 
of the endothelial differentiation gene (EDG) family of G protein-coupled receptors. S1P 
functions extracellularly via the S1P receptors to regulate many important cellular processes 
e.g. cell survival, motility, angiogenesis, immunity and cytoskeletal rearrangement (Fig 3). 
Studies have reported that S1P may also have intracellular functions regulating calcium 
homeostasis, cell growth and suppression of apoptosis [33, 34]. S1P generated by SK1 can 
bind intracellularly to TRAF2 protein to regulate NF-κB function. S1P formed by nuclear 
SK2 directly targets histone deacetylases 1 and 2 (HDAC1/2) activity which links S1P to 
epigenetic regulation of gene expression, and regulate transcription of p21 and c-Fos genes, 
and also binds to prohibitin 2 (PHB2) in the mitochondria to regulate cytochrome c oxidase 
(Cox-2) [35, 36].  
Functions of SKs depend on the level of expression of the enzymes and external stimuli and, 
or protein-protein interactions. Interaction with ERK1/2, Lyn/Fyn [37, 38], δ-catenin [39], 
and elongation factor 1 alpha (eFF1A) [40] proteins may increase the activity of SK1 
whereas, PP2A [41], four and a half LIM domains protein 2  (FHL-2 ) [42], platelet and 
endothelial cell adhesion molecule 1 (PECAM-1) [43] and aminoacylase 1 [44] may decrease 
the catalytic activity of SK1 as reviewed by Pitson [45]. A number of factors and stimuli 
including growth factors, cytokines, oncogenes and even S1P can activate SK1 [45, 46]. 
Activation of SK1 includes its phosphorylation on Ser225 by extracellular signal-regulated 
kinase (ERK) 1/ 2 which does not affect its affinity towards sphingosine or ATP but increases 
its catalytic activity by 14-fold. Conversely SK1 undergoes dephosphorylation by protein 
phosphatase 2A (PP2A) [41]. SK1 activity includes not only its phosphorylation but also its 
translocation to the cell membrane. Phosphorylation-dependent translocation of SK1 to the 
plasma membrane is essential for its oncogenic potential, which is mediated by calcium- and 
integrin-binding protein 1 (CIB1) [47-51]. Recombinant human SK1 produced in bacteria 
was active implying that catalytic activity of SK1 is not dependent on its post-translational 
modification [52]. Post-translational modification of SK1 by acetylation leading to protein 
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stabilization was reported [53]. Research about SK2 activation and its function in normal- 
and disease conditions is increasing but a little is known to date. SK2 has been shown to 
promote colorectal cancer cell proliferation and invasion by enhancing MYC expression [54]. 
Sarah Spiegel and co-workers have shown activation of SK2 by epidermal growth factor 
(EGR) and phorbol ester, which is dependent on extracellular signal–regulated kinase 
(ERK1) signaling in a breast cancer cell line model [55].  
 
Figure 3 SK1/ S1P signaling and intracellular targets of S1P 
The SK/S1P signaling pathway includes the activation of SK1 by agonist-mediated receptor action. Activated 
SK1 translocates to the inner leaflet of the plasma membrane to phosphorylate sphingosine to S1P. Generated 
S1P is then transported outside the cell by S1P transporters and engage in an autocrine or paracrine fashion to 
S1P receptors to induce an array of downstream mechanisms. S1P generated by SK1 can also bind intracellularly 
to TRAF2 protein to regulate NF-κB function. Moreover, S1P generated by SK2 interacts with HDAC1/2 in the 
nucleus to regulate transcription of p21 and c-Fos genes, and also binds to prohibitin 2 (PHB2) in the 
mitochondria to regulate cytochrome c oxidase (Cox-2). HDAC, histone deacetylases; PHB2, prohibitin 2. 
Image was adopted with permission from REF [36]. 
1.1.3 Sphingolipids in cancer 
As a result of the opposing functions of ceramide and sphingosine compared to S1P, it was 
assumed that cell fate is dependent on the balance between these two pools. Therefore the  
‘sphingolipid rheostat’ theory was proposed in 1996 and has been well recognized afterwards 
[19, 56, 57]. Being the regulator of the ‘sphingolipid rheostat’ SK1 was recognized to be one 
of the key determinant of cell viability or death. Years of studies to understand how the 
‘rheostat’ functions and what are the implications eventually led to the findings that S1P and 
ceramide play vital roles in the etiology of several cancers. Additionally, the complexity of 
the interplay between ceramide, sphingosine, and S1P and how they regulate cellular 
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responses were investigated [19]. Ceramide is generally regarded as a tumor suppressor, 
which affects cell cycle progression and promotes apoptosis and autophagic cell death. It 
hereby inhibits cell growth, and enzymes regulating ceramide levels in the cells are 
dysregulated in cancers [58-60]. Sphingolipid-metabolizing enzymes and receptors are 
subject to modification in human cancers, which affects cellular signaling e.g. through 
transactivation of tyrosine kinase receptors (RTKs), complex formation or amplification of 
regulatory loops [61-64]. SK1 and its phosphorylated product S1P are potential therapeutic 
targets because of their involvement in cancer pathogenesis. SK1 expression in cells has 
protective effects against TNF-α and Fas ligand-mediated apoptosis [65] and mediates cell 
survival under starvation and stress [66]. SK1 has been attributed to have oncogenic 
functions, and shorter survival time and poor prognosis have been observed in glioblastoma 
multiforme patients with higher tumor SK1 levels compared to those with lower levels [67]. 
Increased expression of SK1 mRNA and/or protein levels have been reported in several 
cancers including stomach, lung, colon, kidney, breast [68], brain [67], hepatocellular 
carcinoma (HCC) [69, 70] and in non-Hodgkin lymphoma [71]. Knockdown of SK1 in the 
MCF-7 breast cancer cells resulted in cell death and apoptosis [72], and SK1 inhibition has 
shown promising results in many xenograft models of cancer [73] and in several genetically 
or chemically induced mouse models of carcinogenesis [74]. High expression of S1PR1 and 
S1PR3 along with SK1, and ERK1/2 has been shown to be associated with tamoxifen-
resistance in breast cancer patients [75]. S1P and SK1 were proposed as novel biomarkers for 
clinical prognosis in breast, prostate and hematological cancers [76]. Inhibition of SK2 has 
been shown to induce apoptosis and suppression of tumor growth in multiple myeloma cells 
as well as in mouse xenograft model by down regulating cMYC and Mcl-1 [77]. Several 
sphingolipids including S1P were reported to be increased in breast tumors compared to 
normal tissues in patients [78]. Sphingosine 1 phosphate lyase (S1PL), functioning at the last 
step of irreversible sphingolipid catabolism, appeared to be dysregulated in colon carcinoma 
[79] and HCC [70]. The glucosylceramide synthesis pathway is considered to have an 
important role in drug resistance in different types of cancer. The levels of glucosylceramide 
synthase and glucosylceramide were increased in drug-resistance breast cancer tissue [80, 
81], epidermoid carcinoma and ovarian adenocarcinoma cell lines [82] . Moreover, inhibition 
of GCS in HCC cells reverted resistance to sorafenib treatment [83]. Inhibition of acid 
ceramidase, which was increased in head and neck cancer tissue samples and correlated with 
cisplatin-resistance, sensitized cells to cisplatin treatment [84]. Moreover, C1P was shown to 
be associated with cell migration and invasion of human pancreatic cells [85]. 
1.1.4 Sphingolipids in inflammation 
Although numerous pathophysiological conditions such as asthma, inflammatory bowel 
disease and autoimmune diseases (e.g. multiple sclerosis and rheumatoid arthritis) can be 
developed from infections or inflammation, sphingolipid metabolism pathways are crucial 
role players at different stages of the development of these disorders [2]. Ceramide, S1P, 
C1P, lactosylceramides, and GM3 gangliosides have been implicated in the inflammatory 
processes [86-89]. Ceramides are considered to be pro-inflammatory, C1P can both pro-and 
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anti-inflammatory depending on the cell types and the role of S1P in inflammation is unclear 
as reviewed in [90]. Nonetheless, among all sphingolipids S1P is considered to be the most 
potent intercellular signaling molecule. It has been implicated in inflammatory processes 
through regulation of inflammation-related genes [91] or by recruiting and activating 
inflammatory cells in response to different stimuli, including the release of cytokines [92-94]. 
Increased level of SK1 was observed in nonalcoholic fatty liver disease in human and in a 
mouse model with activation of NF-κB, increased cytokine production and infiltration of 
immune cells suggesting a role of SK1 in inflammation in this disease [95]. Initiation and 
progression of ulcerative colitis and inflammatory bowel disease in patient and mouse models 
are correlated with increased activity of SK/ S1P [96]. 
1.1.5 Pharmacological inhibitors of the SKs/ S1P axis 
In cancer the therapeutic aim is to increase the level of pro-apoptotic ceramide by lowering 
anti-apoptotic and angiogenic S1P. Years of research in this area generated several inhibitors 
that target SK1 or SK2 as well as molecules or antibodies targeting S1P or its receptors [60]. 
French et al. screened several non-lipid compounds in order to identify effective inhibitors of 
SK in 2003. Among them SKI-II was found to be highly potent and most selective SK 
inhibitor, and did neither inhibit other recombinant kinases nor compete for the ATP-binding 
site. SKI-II has also shown anti-proliferative and anti-tumor activities in cell lines and in an 
animal model [68, 97, 98]. SKI-II can induce proteasomal degradation of SK1, and it has 
recently been shown to also inhibit dihydroceramide desaturase [99, 100], which led to the 
induction of growth arrest in prostate cancer cells [101]. Combined treatment with SKI-II and 
temozolomide has shown to induce glioblastoma cell death by accumulating dihydroceramide 
and dihydrosphingosine, endoplasmic reticulum stress and autophagy [102]. ABC294640, an 
inhibitor of SK2, was shown to be promising in combination with sorafenib to treat mouse 
models of HCC, kidney carcinoma and pancreatic adenocarcinoma [103, 104]. FTY720 
(Fingolimod, Gilenya®) is in clinical use for treating relapsing forms of multiple sclerosis has 
also shown promising anti-tumor activity in HCC [73]. It is a structural analogue of 
sphingosine, which is synthesized from the fungal metabolite myriocin, and substrate of SK2. 
Its phosphorylated form FTY720-P induces internalization and degradation of the SIPR1 
receptor, and therefore inhibits lymphocyte egress from secondary lymphoid tissues [105]. 
FTY720 can have a number of different biological effects including antitumor activity which 
are not dependent on its phosphorylation and S1PR-interactions [106]. FTY720 is a 
competitive inhibitor of SK1 and induce proteasomal degradation of the enzyme in breast and 
prostate cancer cells [107, 108]. Moreover, it inhibits PI3K/AKT, adapter protein 14-3-3 and 
cytosolic phospholipase A2 (cPLA2), whereas it activates protein phosphatase 2A (PP2A) and 
caspases [105, 106]. FTY720 has also been shown to inhibit CerS and thereby interfere with 
de novo synthesis of ceramide [109-111].  It has been shown to enhance chemo-sensitivity of 
colon cancer cells to doxorubicin [112] and radiation sensitivity of breast cancer cells [113]. 
Moreover, there are ongoing studies to inhibit S1P by using antibodies for treating metastatic 
renal cell carcinoma [114, 115]. 
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1.2 CANCER 
Cancer is the name given to a collection of more than 100 related diseases with diverse risk 
factors. It can originate from most cell types and organs in human, sustain proliferation and 
metastasize to other distant organs. Cancer is an evolutionary process, which develops from 
continuous alteration of inheritable genes in cells followed by natural selection processes 
acting on the acquired phenotypic diversity [116]. According to the list of National Cancer 
Institute, there are around 200 different cancer types based on organ location [117]. Normal 
cells have tight regulation over production and release of cell cycle and growth signals, 
survival, and energy metabolism to maintain tissue homeostasis to keep normal tissue 
functions and architecture. In the process of carcinogenesis, cells deregulate these signals and 
energy metabolism to become master of their own destiny. Cancer cells can sustain 
proliferation in a number of different alternative ways: by producing growth factor ligands for 
autocrine growth signals, by stimulating normal cells in the supporting tumor-stroma, by 
elevating receptor proteins rendering these cells hyper-responsive to the growth factors, and 
by averting growth factor dependency by constitutive stimulation of components of signaling 
pathways operating downstream of these receptors [118-120]. In 2000 Hanahan and 
Weinberg proposed six biological capabilities termed as ‘hallmarks of cancer’ in order to 
better understand the complexities of this disease. The hallmarks are sustaining proliferative 
signaling, evading growth suppression, resisting cell death, limitless replicative potential, 
sustaining angiogenesis, and tissue invasion and metastasis [121]. Two more hallmarks were 
added to this list in 2011, which are reprogramming of energy metabolism and escaping 
immune destruction [120]. Cancer heterogeneity, underlying complexities, adoptability to 
treatments, evasiveness have been addressed during the last 40 years of research, yet 
persistent disease free responses are rare, and cures even rarer for most forms of cancer [122].   
1.2.1 HEPATOCELLULAR CARCINOMA 
Primary liver cancer is the sixth most common cancer worldwide and is the third most 
common source of cancer-related death globally [123, 124]. Geographically, the incidence of 
HCC is not evenly distributed worldwide; Sub-Saharan Africa and East Asia have the highest 
incidence of HCC. Where as, United States and European countries have relatively low 
incidences [125]. According to the annual update report of the United States on cancer, 1975-
2012, overall cancer incidence and death has decreased with the exception of liver cancer. 
Death and incidence of liver cancer has increased greatly in both sexes. The incidence rate 
was twice as high in men than in women and the increase in the incidence is related to the age 
for both sexes [126]. European countries have a slightly higher incidence of HCC relative to 
United States. Central European countries, where male versus female ratio is more than 4:1, 
have reported the highest gender difference in HCC incidence [125]. In 2008 the incidence 
rate of HCC in Sweden was 3.2 in male and 1.4 in female; the incidence rate was adjusted to 
age and calculated per 100,000 liver cancer cases in Europe [127]. Underlying liver diseases, 
resistance to the existing chemotherapy, and late diagnosis due to insufficient surveillance of 
risk groups such as, patients with cirrhosis are the important reasons for the lethality of liver 
cancer. Liver cancer is composed of histologically discrete primary hepatic neoplasms 
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including hepatocellular carcinoma (HCC), intrahepatic bile duct carcinoma or 
cholangiocarcinoma, bile duct cystadenocarcinoma, hepatoblastoma, haemangiosarcoma, and 
epitheliod haemangioendothelioma [128]. Approximately 90% of all cases of primary liver 
cancers are HCC. The main risk factors for developing HCC in China is hepatitis B virus 
(HBV) infection; in Japan is infection with hepatitis C virus (HCV); in U.S.A and Europe are 
infection with HCV, non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease 
(ALD). Other risk factors include liver cirrhosis, fungal metabolite aflatoxin B1 ingestion, 
tobacco smoking and diabetes mellitus [125, 129, 130]. 
1.2.2 Signaling pathways in HCC 
Development of HCC is a multi-step, complex process that results from significant 
accumulation of genetic and epigenetic modifications.  Each HCC consists of an average of 
40 genomic alterations; among them a few are considered to be the driver mutations. Genetic 
alterations in HCC are linked to the underlying risk factors and co-operate with each other in 
the process of carcinogenesis. Common mutations in HCC affect telomere maintenance 
(mutations in telomere reverse transcriptase (TERT)) [131], chromatin remodeling [132, 
133], p53 signaling [134, 135], WNT–β-catenin pathway activation [136, 137], VEGF, 
PDGF, EGF, RAS–RAF–MAPK and PI3K/AKT signaling pathway activation [138, 139], 
oxidative stress pathways activation [136], and mammalian target of rapamycin (mTOR) 
signaling pathway (Fig 4). Cumulative effects of these pathway alteration results in increased 
angiogenesis, cell proliferation, metastasis, inflammation, escape from apoptosis and drug 
resistance [130, 139, 140].  
Additionally, p62 and autophagy play important role in the process of developing HCC. 
Accumulation of p62 has been reported in HCC patient samples [141], which is supposed to 
be cleared from the cells by a functional autophagy. p62 is involved in the process of 
carcinogenesis by preventing cell death during oxidative damage and other stress conditions. 
It acts as a signaling hub, which harbors functional motifs for several important signaling 
molecules including microtubule-associated protein 1 light chain 3 (LC3) interacting region 
(LIR), tumor necrosis factor receptor-associated factor (TRAF) 6 binding site (TB). p62 
activates mechanistic targets of mTOR complex 1, nuclear factor erythroid 2-related factor 
(Nrf2), and nuclear factor kappa-B (NF–κβ). These activated pathways are responsible for 
nutrient sensing (by mTORC1), induction of antioxidant transcription (by Nrf2) and 
inflammatory responses (by NF–κβ) [142-147].  
Alteration of sphingolipid metabolism has been shown to be associated with many different 
kinds of cancer. In HCC patients with underlying liver disease increased serum levels of C16-
ceramide and S1P were reported. This may serve as novel diagnostic markers for the 
identification of HCC in patients with liver diseases [148]. Studies have shown that increased 
mRNA expression of Sphk1 and S1PL in HCC is related to poor differentiation and micro-
vascular invasion [69, 70]. On the other hand, higher level of SK2 mRNA expression was 
associated with intra-and extra-hepatic recurrence [70]. Increased level of GCS was reported 
in sorafenib-resistant cell lines. Levels of GCS, acid sphingomyelinase (ASMase) and Sphk1 
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mRNA were increased following sorafenib treatment in HCC cell lines. These cell lines 
together with a xenograft mouse model were sensitized to sorafenib treatment after inhibition 
of GCS [83]. Recombinant human acid sphingomyelinase was also studied in combination 
with sorafenib in experimental HCC model in order to increase sorafenib-mediated treatment 
efficacy [149]. 
 
Figure 4 HCC progression and driver genes  
Major recurrent molecular defects that are observed early in liver carcinogenesis. TERT promoter mutations are 
common early events that are identified in most cases of HCC. Other mechanisms are specifically related to risk 
factors; for example, HBV and adeno-associated virus 2 (AAV2) infections. Moreover, hepatocellular adenoma 
(HCA), a rare benign liver tumor occurring most frequently in women who take oral contraception, can 
transform into HCC. CCN, cyclin; FRK, fyn-related Src family tyrosine kinase; GNAS, GNAS complex locus; 
HNF1A, hepatocyte nuclear factor 1α; IL6ST, interleukin 6 signal transducer; JAK1, Janus kinase 1; KMT2B, 
lysine (K)-specific methyltransferase 2B. Image was adapted with permission from REF [130]. 
1.2.3 Treatment options for HCC 
Molecular classification of HCC is not established yet, and Barcelona Clinic Liver Cancer 
(BCLC) staging classification (Fig 5) is the set of criteria that is used to guide management of 
patients with hepatocellular carcinoma. Vaccination against HBV has been demonstrated as 
primary prevention of HCC. In patients with chronic infections, antiviral therapies for HBV 
and HCV that offer prolonged virological responses are effective in reducing HCC incidence 
[127, 130]. According to BCLC guidelines, treatments for very early stages HCC are 
resection, liver transplantation, and local ablation with radiofrequency, microwave or 
percutaneous ethanol injection; intermediate stage HCC is trans-catheter chemoembolization 
(TACE); advanced stage HCC is systemic therapy with sorafenib; whereas end stage HCC 
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patients are given palliative support including pain management, nutrition and psychological 
care [127]. 
Sorafenib is a standard systemic treatment, which received FDA approval in 2006 for treating 
advanced HCC with preserved liver function, i.e. BCLC stage C. Yet there is no available 
clinical or biological biomarker to identify best responders to sorafenib treatment and there is 
no second-line therapy for non-responders to sorafenib treatment [127]. Sorafenib is a multi-
kinase inhibitor, which targets serine/threonine and receptor tyrosine kinases, predominantly 
vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor 
(PDGFR), c-Kit and RET to decrease tumor growth and angiogenesis. VEGFR, PDGFR, 
fibroblasts derived growth factor receptor  (FGFR), and insulin growth factor receptor (IGFR) 
are all perturbed in the process of HCC development [150-152]. Side effects related to 
sorafenib treatment include diarrhea, hand and foot reaction and fatigue. Treatment efficacy 
of sorafenib-targeted therapy is limited to a median of 3 months increase of overall survival. 
Limitations of sorafenib treatment are limited survival benefit, necessary exclusion of 
patients with impaired liver function and inefficiency of using it in the adjuvant settings. 
There are numerous phase II and III trials investigating first-line or second-line therapies with 
other compounds but most of them failed to produce any successful results. Limited success 
in treating HCC is predicted to be due to tumor heterogeneity, diverse mutations and 
perturbations in the signaling pathways and underlying liver diseases [130, 151, 153]. Studies 
with several targeted therapy, e.g. Brivanib [154] and sunitinib were promising but failed to 
prove better efficacy over sorafenib or exhibited severe side effects, respectively. Somewhat 
more promising outcomes have emerged from ramucirumab, a recombinant monoclonal IgG 
antibody with specificity towards VEGFR2 and regorafinib, a multikinase inhibitor that are 
currently undergoing phase III clinical trial as a second-line treatment option for a subgroup 
of patients [130, 151, 152]. Most of the phase III drugs currently being tested are anti-
angiogenic agents, immune checkpoint inhibitors, cell-cycle blockers or receptor tyrosine 
kinase inhibitors. Based on the genomic studies performed during the last decade, HCC has 
been classified to have either proliferative (HBV related) or non-proliferative (HCV and 
alcohol related) genotypes, comprising 50% of patients in each group [138].  Lack of 
knowledge about main driver mutations and corresponding pathways, and biomarker 
stratification are assumed to be the reasons for being failure in the drug trials [130, 151]. 
Since sorafenib treatment is the standard of care, it is suggested from the American 
Association for the Studies of Liver Diseases and Journal of the National Cancer Institute to 
combine new molecules tested in the first-line settings with sorafenib, to demonstrate 
superiority [151, 155]. 
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Figure 5 Management of HCC according to Barcelona Clinic Liver Cancer 
There are five stages of HCC in BCLC classification in order to choose the best therapies for the best matched 
candidates. Stages 0–A patients are with asymptomatic early tumors; stage B patients are with multi-nodular 
HCC; stage C patients are at advanced stage, symptomatic HCC with portal vein invasion; stage D, which is the 
end stage with poor prognosis. PS, performance status. Case courtesy of Dr Matt A. Morgan, Radiopaedia.org, 
rID: 34365. 
1.2.4 BLADDER CANCER 
The ninth most common cancer in the world is bladder cancer (BC), which is also the most 
common cancer of the urinary tract [156, 157]. According to GLOBOCAN estimate, there 
were 430 000 new cases and 165 000 death from BC occurred worldwide in 2012. BC is 
more prevalent in males than females. Geographically it is predominant in Southern and 
Western Europe, North America, and certain countries in Northern Africa and Western Asia. 
In Europe the highest incidence was in Southern Europe (Spain and Italy) followed by the 
Nordic countries (e. g, Denmark: Age Standardized Rate = 27.4 per 100 000) [157]. In 
Sweden 2793 cases of urinary bladder cancer were diagnosed in 2011, among them 2049 
were in men and 744 were in women. This constitutes 6.8% of all cancers in male and 2.7% 
of all cancer cases in women [158]. The most significant risk factor of BC is age and the 
median age at diagnosis is around 70 years. Environmental risk factors play a vital role in the 
development of bladder cancer. Among which tobacco smoking (>50% of bladder cancer) 
[159, 160], occupational exposure to aromatic amines and other chemicals (paints, dye, 
rubber, or aluminum industries workers) [160], chronic urinary tract infection, and 
Schistosomiasis (prevalent in Egypt) are the important risk factors [161, 162].   Genetic risk 
factors include polymorphisms in two carcinogen-detoxifying genes, N‑acetyltransferase-2 
(NAT2) and glutathione S‑transferase‑µ1 (GSTM1). Single-nucleotide polymorphisms 
(SNPs) that are associated with moderate risk of bladder cancer are close to the genes MYC, 
TP63, prostate stem cell antigen (PSCA), telomerase reverse transcription (TERT), 
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fibroblasts growth factor receptor 3 (FGFR3), cyclin E1 (CCNE1), and UDP 
glucoronosyltransferase 1 family and polypeptide A complex (UGT1A) [159, 160, 163].  
Histologically  >90% of the bladder cancers are transitional cell (urothelial) carcinomas 
(TCC), ∼5% are squamous cell carcinomas, and <2% are adenocarcinomas [164]. These 
tumors are classified based on World Health Organization (WHO) grading in 1973 and 2004, 
which is based on the cellular characteristics, and staging is based on the tumor-node-
metastasis (TNM) system (Tis-T4) (Fig 6). Grossly bladder cancer can be divided into non-
muscle-invasive (NMIBC) and muscle invasive bladder cancer (MIBC). The majority of the 
patients (∼75%) with BC present with a disease confined to the mucosa (stage Ta, carcinoma 
in situ (CIS)) or submucosa (stage T1). Due to long-term survival and lower risk of cancer 
specific mortality compared to T2-4 tumors, they have a higher incidence. The majority of 
the TCCs are low-grade papillary tumors (Ta) at the time of diagnosis. Stage T1 tumors 
which have invaded lamina propria but not inner muscles are high grade as are MIBC. 50-
70% of NMIBCs recur but invasion to muscle is not very common (10-15%) [163]. 
Carcinomas in situ (CIS/ Tis) are flat, high-grade tumors that are confined to the mucosa. CIS 
and T1 lesions have shown high malignancy potential in both clinical practice and molecular 
biology techniques. About 54% of the patients with CIS develop MIBC within 5 years span if 
untreated [164, 165].  
 
Figure 6 Staging and grading of bladder cancer 
a. Bladder cancer staging according to the Tumor-Node-Metastasis (TNM) system. b. Grading according to the 
1973 WHO and 2004 WHO/ International Society of Urological Pathology (ISUP) criteria. PUNLMP = 
papillary urothelial neoplasm of low malignant potential; Image was adopted with permission from REF [163] 
Hematuria is the most common symptom in patients, which is recommended to follow up by 
physical examination, cystoscopy, urinary cytology, and biopsy [166]. Transurethral resection 
(TUR) is a treatment option for NMIBC. To delay disease recurrence, surgery may be 
followed by instillation of chemotherapeutic agents (e.g. mitomycin C). Thereafter, patients’ 
urine sediments are followed up by cytological examination and periodic cystoscopy is 
performed [163, 165]. Intravesical Bacillus Calmette-Guérin (BCG) is the standard treatment 
for high-risk, NMIBC including CIS, high-grade papillary tumors (stage Ta), and lamina-
propria-invasive tumors (Stage T1). Treatment with BCG is associated with a lower risk of 
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disease recurrence compared to TUR alone and BCG can also minimize the risk of 
progression to invasive disease [167]. 
1.2.5 BCG treatment in bladder cancer 
In 1921 Albert Calmette and Camille Guerin succeeded in attenuating the cow tuberculosis 
bacillus, Mycobacterium bovis at the Pasteur Institute of France [168]. BCG eventually 
became an effective vaccine for preventing human tuberculosis regardless of the less 
virulence capacity [169]. The idea of using BCG in treating cancer was triggered by an 
autopsy study by the biologist Raymond Pearl that patients with tuberculosis had seemingly 
lower incidence of cancer [170]. Holmgren first reported the use of BCG inoculation as an 
anti-cancer treatment option in 1935 [171]. Numerous research have been done on the use of 
BCG in different types of cancer albeit its use in bladder cancer was stemmed out after Coe 
and Feldman’s findings that bladder is an immuno-competent organ and responsive to topical 
BCG [172]. Morales et al first described successful intravesical BCG treatment in recurrent 
BC in 1976 [173]. After Morales success in 1980 Lamm et al showed in a randomized study 
that BC recurrences dropped from 42% to 22% when BCG instillation was combined with 
endoscopic management compared to endoscopic management alone [174]. Since then BCG 
instillation has been established as the standard treatment following TUR of high-risk 
NMIBC. Most clinical practice guidelines recommend maintenance therapy with BCG for 1–
3 years [175]. BCG is administered through a urethral catheter and patients are suggested to 
retain it for 1-2 hours [165]. The exact mechanisms of action of the antitumor effects of BCG 
is yet unknown.  
Antitumor activity of BCG depends on adequate stimulation of patient’s immune system, live 
BCG and contact of BCG with bladder cancer cells [176, 177]. Following BCG instillations 
their attachment to the urothelial wall is facilitated by fibronectin [178]. Thereby BCG is 
internalized by urothelial and dendritic cells resulting in the release of a number of cytokines, 
including interleukin 6 (IL-6) and granulocyte-macrophage colony-stimulating factor (GM-
CSF). Consequently macrophages, granulocytes and leucocytes are recruited locally. Cell 
death occurs from direct cytotoxicity of BCG and the release of different apoptotic factors 
[179, 180].  Macrophages are believed to play a crucial role in BCG mediated antitumor 
activity. Increased number of macrophages and cytokines were found in the voided urine of 
BC patients following BCG treatment. After BCG treatment macrophages can also be found 
in the bladder wall of patients [181-183]. BCG stimulated macrophages have shown to induce 
cytotoxicity in several bladder cancer cells in vitro [184-187]. Many of the cytokines secreted 
in the urine of BC patients after BCG treatment are found to be secreted by BCG stimulated 
macrophages e.g. IL-1β, IL-6, IL-8, IL-10, IL-12, interferon-γ, and TNF-α [188-190]. Even 
though immunotherapy with BCG is the golden standard adjuvant treatment for high-risk 
NMIBC, more than 30% of the patients fail the treatment [191] and the disease recurs in 
around 20% of the patients [192, 193]. A number of BC patients are intolerant to BCG 
treatment because of side effects ranging from cystitis, irritation during voiding to uncommon 
but life-threatening BCG sepsis [194, 195]. 
  21 
1.2.6 Signaling pathways involved in bladder cancer 
There is a need for molecular biomarkers for diagnosis and development of effective 
treatment of bladder cancer. Point mutation of the TERT promoter region and mutation of 
FGFR3 are the common genetic alterations discovered till now [196-198]. In vitro FGFR3 
mutation activates RAS-MAPK pathway and phospholipase Cγ leading to survival and 
proliferation of urothelial cells [163]. Disruption of p53 signaling and activation of RTK 
signaling followed by activation of PI3K/AKT/mTOR pathways have been correlated to poor 
clinical outcomes, progression to invasive BC and resistance to therapy [199-201]. To date, 
not much is known about sphingolipid metabolism status in bladder cancer. In 2014 it was 
shown for the first time that BC tissues express a high level of SK1 mRNA and protein. High 
level of SK1 was strongly associated with histologic grade, tumor stage and reduced overall 
5-year survival rates.  The study suggested that SK1 is an independent prognostic factor for 
poor disease outcome [202]. Moreover, gangliosides were found to be accumulated in 
superficial papillary tumors compared to the invasive tumors [203]. Overexpression of 
ganglioside reduced cell proliferation, motility, and invasion and induced apoptosis of murine 
bladder cancer (MBT2) cells and reduced tumor growth in a xenograft mouse model [204]. 
Additionally, local or exogenous administration of GM3 ganglioside inhibited both invasion 
and growth in xenograft mouse model [203, 205]. 
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2 AIMS 
The aims of this thesis were to target sphingolipid-metabolizing enzymes in order to study the 
effect of cytotoxic treatment on the levels of a subset of sphingolipids, to investigate whether 
treatment with inhibitors of SKs could enhance the cytotoxicity, and to elucidate mechanisms 
behind possible effects of combined treatment in HCC and bladder cancer cells. 
Study specific aims were: 
Paper I: to investigate the cytotoxic effects of selenite treatment in the presence of inhibitors 
of sphingolipid-metabolizing enzymes in a hepatocellular carcinoma cell line.  
Paper II: to sensitize hepatocellular carcinoma cell lines to sorafenib-mediated cytotoxicity by 
cotreatment with the sphingosine analogue FTY720.   
Paper III: to study the treatment effects of BCG in combination with an inhibitor of SKs in 
urothelial bladder cancer cell lines.  
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3 MATERIALS AND METHODS 
This section will focus on general discussions about some of the models and methods used in 
this thesis. More detailed and study-specific protocols are described in the individual papers. 
3.1 Cell lines 
Cell lines are widely used models in in vitro research due to accessibility to large pool of 
samples, ease of handling, relative low cost and flexibility to test different therapeutic agents. 
Several immortalized cell lines were used as research model in our studies. In paper I and II 
human hepatocellular carcinoma cell lines Huh7 and HepG2, and the close to normal 
immortalized liver cell line MIHA were used. The Huh7 cell line is derived from well-
differentiated hepatocellular carcinoma containing mutated p53 [206]. Acknowledging the 
extreme heterogeneity of advanced HCC we have also used the HepG2 cell line that has wild-
type p53 phenotype [207]. In paper III, we have used the murine bladder cancer cell line 
MBT2, the human bladder cancer cell line T24 and the murine macrophage cell line RAW 
264.7. In this study it was important to mimic the in vivo response to BCG treatment in vitro 
by provoking an immune response by stimulating macrophages with BCG before treating 
bladder cancer cells with supernatant from the BCG-treated macrophages. As human 
macrophage cell lines respond poorly to BCG, we were limited to use murine cell lines in this 
model system.  
Wilding and Bodmer have reviewed pros and cons of using different in vitro and in vivo 
models. Some crucial disadvantages of using cell lines as research model particularly in drug 
development are: genetic changes during cell culturing, lack of tumor heterogeneity present 
in primary cancers and lack of appropriate tumor micro-environment. Having acknowledged 
the aforementioned cons cell lines are still very useful research tools in preclinical in vitro 
studies before proceeding to animal/ human trials [208].  
3.2 Proliferation and cytotoxicity assays 
Uncontrolled proliferation is one of the most important characteristics of cancer cells. 
Successful cancer treatment depends on cytotoxicity of the treatment agents towards 
malignant cells. The aim of developing effective cancer treatment is therefore to kill 
malignant cells while keeping the normal cells unaffected. There are different methods to 
assess cytotoxicity of pharmacological agents in vitro. Some of the commonly used assays 
are: WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphonyl)-2H-
tetrazolium], MTT assay, XTT sodium 3'-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis 
(4-methoxy-6- nitro) benzene-sulfonic acid hydrate assay, trypan blue cell exclusion method, 
5-bromo-2´-deoxyuridine (BrdU) incorporation assay, propidium iodide (PI) staining of the 
nuclei, alamar blue and lactade dehydrogenase (LDH) leakage assay.  
The XTT assay, which is a colorimetric assay for non-radioactive quantification of cell 
proliferation and viability, was used in all of the papers. XTT is a tetrazolium salt that 
becomes formazan dye by the metabolic activity of mitochondrial dehydrogenases of live 
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cells. Formed formazan dye is water soluble and orange in color, which can be measured by 
spectrophotometers. The more viable cells present in the samples the higher will be the 
absorbance and vice-versa. XTT is a widely used method for its sensitivity and convenience 
of use. It might be important to thoroughly re-consider using this method if the therapeutic 
agent is expected to alter the metabolic state of the cells to avoid false positive or false 
negative results.  
The trypan blue exclusion method was used in paper I and III. This method uses the principle 
that cell membrane integrity is compromised during cell death allowing penetration of dyes 
into the cytoplasm. Live cells are impermeable by trypan blue, and therefore glowing, 
unstained cytoplasms are easily visible under light microscope. This method is widely used 
because of its rapidity, cost-effectiveness and accuracy. It is a very stable method to count 
live cells, yet might not be the best choice studying cytotoxicity. Cells that are still alive but 
have compromised growth and cell function will not be distinguished by this method. On the 
contrary, cells having transient membrane permeability due to mechanical or other stress will 
be stained with trypan blue. During large-scale and time-course experiments, it is almost 
impossible to use this method as trypan blue itself is cytotoxic when used in long-term 
incubations. 
Replication states of cells following treatment with anticancer drugs can be analyzed by 
staining the nuclei of cells with fluorescence dyes. Light scattering characteristics of up taken 
propidium iodide (PI) are capitalized in this method. According to the protocol, cell 
membrane lipids are dissolved using a nonionic detergent, the cell cytoskeleton and nuclear 
proteins are eliminated with trypsin, cellular RNAs are digested with an enzyme, and the 
nuclear chromatins are stabilized with spermine. PI stoichiometrically binds to the clean, 
isolated nuclei, which are then analyzed by flow cytometry. PI-stained nuclei emit fluorescent 
light primarily at wavelengths between 580 and 650 nm. The resulting histogram consists of 
three populations, two Gaussian curves for the G1- and G2 populations and another for S 
phase population. Quiescent and G1 cells have one copy of DNA and therefore have 1X 
fluorescence intensity, whereas cells in the G2/ M phase of the cell cycle have double DNA 
copies and therefore have 2X intensity. On the contrary, the cells in S phase are in the DNA 
synthesis phase and therefore have fluorescence intensity between the 1X and 2X 
populations. This is a very robust way of determining cell cycle progression and cytotoxicity 
but at the same time it is tedious and time consuming. 
In paper II, the Annexin-V-FLUOS staining kit (Roche Diagnostics GmbH, Germany) was 
used to measure cell death. One of the changes occurring in the cell surface of early apoptosis 
is externalization of phosphatidylserine (PS) to the cell surface. PS translocation occurs by 
the enzyme flippase during necrosis as well but during necrosis, cell membranes become 
leaky and ruptured where as in early apoptosis cell membranes are intact. According to this 
method, fluorescein isothiocyanate (FITC) labeled Annexin-V binds to phosphatidylserine in 
the outer leaflet of apoptotic cell membranes, whereas PI binds to the nuclei of the necrotic 
cells, thereby differentiating apoptotic and necrotic or late apoptotic cells. Annexin-V, which 
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is a Ca+ dependent phospholipid binding protein has high affinity towards PS. Therefore 
combining annexin-V with PI will result in cell populations that are FITC-/PI- (healthy cells), 
FITC+/PI- (early apoptotic cells) or FITC+/PI+ (necrotic cells). These discrete cell 
populations are then detected by analyzing the samples in a flow-cytometer [209, 210].  
Microscopy is a powerful technique to visualize morphological features of cells or tissues. In 
paper I and II we have used fluorescent and confocal microscopy to determine features of 
apoptotic cell death. During apoptosis biochemical and morphological changes occur in the 
cells. Cell shrinkage, surface blebbing, and chromatin condensation leading to nuclear 
fragmentation are some of the morphological characteristics during apoptosis. In our study 
we have used DAPI, which exclusively stains nuclei that is visible under fluorescent or 
confocal microscope by using appropriate filter. Treated cells were processed and fixed on 
the cover slips and visualized for changes in the nuclei. 
3.3 Messenger RNA and protein assays 
Real time quantitative PCR is widely used in medical research to study gene expression in 
many different settings including in different disease or treatment conditions. Accuracy and 
specificity of this method is largely dependent on design of primer-probe and use of 
appropriate house keeping genes. In order to choose the most stable reference gene in our 
study, 8 different reference genes (e.g. 18S, Actb, B2m, Gapdh, Gusb, HPRT1, Pgk1 and 
Tfrc) were screened. HPRT1 showed very stable expression levels therefore, we chose to 
continue using it [211].  
In paper I we have used cell death ELISA (Roche Diagnostics, Basel, Switzerland) to detect 
histone and intra-nucleosomal DNA fragmentation. It is a quantitative sandwich ELISA that 
capitalizes specificity of two different monoclonal antibodies. This allows specific 
determination of mono-nucleosomes and oligo-nucleosomes in the cytoplasmic fraction of 
the cell lysates. The micro-plate wells were coated with the anti-histone-biotin antibody; 
nonspecific binding sites are saturated by treatment with blocking solution, and binds to 
histones H1, H2A, H2B, H3 and H4. The anti-DNA-peroxidase antibody binds with double 
and single stranded DNA in the cytoplasm. After removal of unbound peroxidase conjugate, 
the amount of peroxidase retained in the immuno-complex is photo-metrically determined 
with ABTS as the substrate. 
In all of the papers we have used western blotting to study the expression of different 
proteins. Western blotting is the transfer of separated proteins from the gel to the surface of a 
thin support membrane matrix. The proteins are bound and immobilized on the membrane. 
Bound proteins are further detected by using HRP- or infra-red (IR) dye-conjugated 
secondary antibodies. In paper I we have used HRP-conjugated secondary antibodies whereas 
in paper II and III we have used IR dye conjugated antibodies along with the more sensitive 
LICOR imaging system. This method is very time consuming and many parameters need to 
be optimized. One of the main hazards is certainly availability of specific and good 
antibodies. To overcome this limitation it is important to validate panel of antibodies by using 
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positive control or recombinant protein, appropriate negative control and blocking peptide. It 
is also recommended to use a stable loading control protein to relate the expression of the 
protein of interest. In our study we have validated antibodies from different companies in 
order to select the suitable one.      
4 RESULTS AND DISCUSSIONS 
4.1 PAPER Ι: Inhibition of sphingosine kinase 1 enhances cytotoxicity, 
ceramide levels and ROS formation in liver cancer cells treated with 
selenite 
Whereas low doses of selenium have been shown to prevent cancer [212], treatment with 
high doses of selenite has previously been shown selective cytotoxicity towards malignant 
[213] and drug-resistant cells [214]. Accumulation of ceramide subspecies and cell death in 
erythrocytes has also been shown after selenite treatment [215]. In our study we have shown 
that after treating Huh7 cells with an EC50 dose of selenite, long chain ceramide subspecies 
(C14-, C16-, C18- and C18: 1- ceramides) increased approximately by two-fold. This result 
implies ceramide formation as a contributor to selenite mediated cytotoxicity in Huh7 cells. 
Increased levels of C16-, C18- and C20-ceramides following cytotoxic treatment of cells of 
different origin have been reported earlier [216, 217].    
We were also interested to know whether the observed accumulation of ceramide after 
selenite treatment was the result of de novo synthesis or the breakdown of sphingomyelin. 
We have observed that blocking de novo ceramide synthesis by myriocin, and acid 
sphingomyelinase by desipramine did not alter the decrease in Huh7 cells viability induced 
by selenite treatment. On the contrary, blocking neutral sphingomyelinase by 3-O-methyl 
sphingosine significantly counteracted the cytotoxicity caused by selenite treatment. In line 
with this observation we have shown increased activity of nSMase following selenite 
treatment. Cellular stress, anticancer drugs, and oxidants have earlier been shown to activate 
nSMase [23]. Our results imply that part of the selenite-mediated cytotoxicity towards Huh7 
cells was mediated by ceramide-formation from sphingomyelin via nSMase. 
We further investigated how selenite treatment affects downstream breakdown of ceramide in 
order to be able to increase treatment efficacy by inhibiting SK1 and GCS. We were mainly 
focused on SK1 and GCS due to their known contribution to promote cancer and drug 
resistance. Selenite treatment previously has been shown to induce reactive oxygen species 
(ROS) [218]. Pretreatment with an inhibitor of SK1 (SKI-II) more effectively enhanced the 
decreased viability following selenite treatment compared to treatment with an inhibitor of 
GCS. Combined treatment with selenite and SKI-II decreased the viability of the 
hepatocellular carcinoma cell line Huh7 without affecting the close to normal hepatocellular 
cell line MIHA. These results suggest that inhibition of SK1 sensitizes Huh7 cells towards 
selenite treatment. 
Investigation of the underlying mechanisms of cytotoxicity observed after combined 
treatment with selenite and SKI-II revealed decreased number of cells in the G2 phase in the 
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cell cycle, nuclear fragmentation and internucleosomal cleavage. From the observations we 
have concluded that combination of selenite and SKI-II induces alteration of the cell cycle 
progression and apoptosis in Huh7 cells. Measurement of ceramide subspecies has shown an 
increase in long chain ceramides after cotreatment with SKI-II and selenite compared to the 
vehicle treated controls. Increase in the ceramide subspecies following inhibition of SK1 
might be explained by earlier studies that N-acetylation of sphingosine by CerS generated 
long to very long chain ceramides [219]. Suggesting that when SK1 was inhibited S1P 
production was blocked and sphingosine was recycled to ceramide. We suggest that the 
accumulation of long chain ceramides and increased cytotoxicity after co-treatment with SKI-
II and selenite in the HCC cell line is the result of ceramide generation from sphingomyelin 
breakdown and recycling of sphingosine. Moreover, treatment with a combination of SKI-II 
with selenite significantly increased ROS formation compared to treatment with SKI-II or 
selenite alone.  
4.2 PAPER II: FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells 
to sorafenib-mediated cytotoxicity 
In this study we wanted to sensitize HCC cells to sorafenib treatment, which is a FDA 
approved small molecule inhibitor to treat unresectable HCC [220] by combining with 
FTY720, which is also approved by FDA to treat multiple sclerosis and has cytotoxicity 
towards HCC cells [221]. In order to combine sorafenib with the least cytotoxic dose of 
FTY720, a dose titration was performed with FTY720 alone towards hepatocellular 
carcinoma cell lines Huh7 and HepG2 cells separately. In all the experiments an increasing 
doses of sorafenib were combined with the least cytotoxic dose of FTY720.  
Following treatment with increasing doses of sorafenib for up to three days the viability of 
Huh7 and HepG2 cells was decreased. The decreased viability was further enhanced after 
combining the sorafenib treatment with FTY720. The effects of combined treatment 
increased over time in Huh7 cells that were also more sensitive to the treatment compared to 
HepG2 cells. 
Cell cycle distribution analysis of Huh7 cells revealed that combined treatment with sorafenib 
and FTY720 caused a significant accumulation of cells in the G1 phase, resulting in the 
concurrent decrease of cells in the S and G2 phases of the cell cycle. At higher doses of 
sorafenib cotreatment with FTY720 has shown significant decrease of cells in G2 phase in a 
time dependent manner. A substantial increase in sub G1 fraction referring to cell debris has 
been observed with increasing doses of sorafenib treatment compared to the vehicle control, 
which has slightly increased after combination with FTY720. 
Cell death analysis of Huh7 cells by annexin V and propidium iodide staining by flow 
cytometry following treatment with sorafenib and FTY720 has shown a significant increase 
in total cell death compared to sorafenib treatment alone. Since it can be difficult to 
distinguish late apoptosis from secondary necrosis, total cell death was calculated as the sum 
of the populations of cells stained with Annexin V only, with Annexin V and PI or with PI. 
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Investigation of PARP-cleavage in Huh7 cells revealed apoptosis following treatment with 
sorafenib alone, which was further augmented when combined with FTY720. PARP-
cleavage is a well-known marker for caspase-dependent apoptosis [222]. Additionally, 
combined treatment with lower doses of sorafenib and FTY720 resulted in slight release of 
apoptosis inducing factor (AIF) and Cyt c from the mitochondria into the cytosol, which was 
slightly augmented after combination treatment. These findings suggest that combined 
treatment of Huh7 cells with sorafenib and FTY720 induces mitochondria-mediated 
apoptosis mostly in a caspase-independent manner but at higher doses of sorafenib, in a 
caspase-dependent manner. 
Finally, we have investigated if autophagy also played a role in cell death mechanisms 
observed after sorafenib and FTY720 combination treatment. A previous study has shown 
that treatment with FTY720 enhanced anticancer efficacy of milatuzumab in mantle cell 
lymphoma by blockage of autophagy [223]. On the other hand, sorafenib treatment was 
associated with induction of autophagy, which might be a way of escaping cytotoxicity [224]. 
We observed that treatment with increasing doses of sorafenib alone slightly increased the 
levels LC3 II, which were further augmented following cotreatment with sorafenib and 
FTY720. Additionally, treatment with increasing doses of sorafenib alone decreased the 
levels of p62 protein, which was reverted after cotreatment with sorafenib and FTY720. 
These results are in line with the aforementioned studies [223, 224] implying that sorafenib 
treatment alone induces autophagy in Huh7 cells whereas FTY720 treatment blocks it. The 
resulting effects along with a summary of our study are depicted in Fig 7. 
 
Figure 7 Summary of cotreatment effects of sorafenib and FTY720 on Huh7 
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4.3 PAPER III: Effects of treatment with Bacillus Calmette-Guérin and an 
inhibitor of sphingosine kinase 1 in urothelial bladder-cancer cells 
(Manuscript) 
In this study, we have investigated if BCG treatment has any effects on the levels of SK1 
RNA or protein as well as how cotreatment with SKI-II and BCG affects cell viability and 
sphingolipid metabolism in bladder cancer cells. In order to mimic in vivo immune response 
in vitro we have stimulated RAW264.7 macrophages with BCG and collected supernatants 
(SupBCG) to treat murine bladder cancer cells (MBT2) with the clear supernatants.   
Previous studies have shown antitumor and cytotoxic effects of SKI-II both in vitro and in 
vivo [68, 97]. We have investigated if treatment with SKI-II in combination with BCG/ 
SupBCG will exert viability reduction in bladder cancer cells. In the human bladder cancer 
cell line T24, significant cytotoxicity was observed only when higher doses of SKI-II was 
combined with direct BCG treatment. In the murine bladder cancer cell line MBT2, a dose 
dependent decrease in viability was observed after treatment with increasing doses of 
SupBCG alone. The decrease was further enhanced after combined treatment with SKI-II 
compared to treatment with SupBCG or SKI-II alone.  
Furthermore, we wanted to know if casepase-mediated apoptosis was involved in the 
cytotoxic effects after SKI-II and SupBCG treatment in MBT2 cells. Treatment with SKI-II 
or SupBCG alone induced substantial PARP-cleavage compared to treatment with 
supernatant from unstimulated macrophages (SupCtr). Nevertheless, no combined effect was 
observed and it should also be noted that the treatment agents did not counteract their 
respective effects on the levels of cleaved PARP either. This observation led to the 
conclusion that there are additional mechanisms of cell death than caspase-dependent 
apoptosis behind the observed decrease in viability following combined treatment with 
SupBCG and SKI-II.   
Our results have shown a significant but transient increase in Sphk1 mRNA expression after 
SupBCG treatment. On the contrary, SK1 protein levels remained unchanged over time 
following treatment with SupBCG. Earlier studies have shown connection between 
cytotoxicity mediated by cytotoxic treatments and increased levels of different chain lengths 
of ceramide subspecies [216, 217]. Thus, we have investigated if SKI-II and/ or SupBCG 
treatment influenced the levels of ceramide subspecies in MBT2 cells. Our results have 
shown that treatment with SupBCG alone did not have a significant influence on the levels of 
analyzed ceramide subspecies. The level of dihydro C16-ceramide was increased after 
combined treatment with SKI-II and SupBCG, whereas the level of C16-ceramide was 
decreased compared to SupBCG treatment alone. Dihydroceramides are the precursors of 
ceramide in the de novo pathway, which undergo N-acylation by the enzyme Des to produce 
ceramide. Additionally, (dihydro) C16-ceramide are the products of both CerS5 and CerS6 
[15]. Previous studies have shown accumulation of dihydroceramide following treatment 
with different substances and as a result of oxidative stress leading to cell cycle arrest and 
autophagy [225]. Accumulation of dihydroceramide level following SKI-II might also be 
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explained by the recent finding that SKI-II not only inhibits SK1 but also Des and led to 
growth arrest [101] . 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
The perspective of the thesis was to study the treatment effects of sphingolipid metabolizing 
enzyme inhibitors: on HCC cell lines following cotreatment with selenite or sorafenib, and on 
bladder cancer cell lines after cotreatment with BCG. Treatment effects were studied by 
investigating the levels of ceramide subspecies, and by studying pathways governing 
cytotoxicity.  
In the first study we have shown that selenite treatment of Huh7 cells increased the levels of 
long chain ceramide subspecies with subsequent increase in nSMase activity. This might 
refer to the activation of sphingomyelin breakdown pathway of ceramide generation followed 
by concomitant decrease in cell viability. Furthermore, cotreatment with SKI-II and selenite 
resulted in increased levels of ceramide subspecies, induction of reactive oxygen species 
formation and apoptosis, and inhibition of cell cycle progression and cell viability. These 
results imply that combined treatment of HCC cells with selenite and inhibition of SK1 might 
be an alternative option to treat HCC. Therefore, it will be required to do further investigation 
in animal models (e.g. humanized mouse model of liver cancer) to test the benefits and 
toxicities of the combination treatment. More specific and novel inhibitors of SK1with better 
bioavailability should be considered. Study of the CerS enzyme following combined 
treatment could provide valuable insights, as ceramide can be recycled from sphingosine 
upon inhibition of its phosphorylation or from sphingomyelin catabolism. 
In the second study we have tested the combination of sorafenib and FTY720 in the treatment 
of HCC cells. Both of the drugs used in this study are FDA approved: sorafenib for treating 
advanced stage, non-resectable HCC, and FTY720 for treating relapsing multiple sclerosis. 
Additionally, FTY720 is a modulator of sphingolipid metabolism. In this study we showed 
that a marginally cytotoxic dose of FTY720 sensitized HCC cell lines towards sorafenib 
treatment. Combined treatment with sorafenib and FTY720 of Huh7 cells resulted in a 
decreased cell viability, cell cycle arrest, apoptosis and blockage of autophagy leading to cell 
death. This study provides solid background for continuing research on signaling pathways 
such as changes in the PI3K and MAPK pathways since both of the substances influence 
these pathways individually. More research should be done to analyze the treatment effects 
on different sphingolipid metabolites, and animal models (e.g. humanized mouse model of 
liver cancer) should be included in the future. 
In the last study we have investigated the combination of a sphingosine kinase inhibitor SKI-
II and supernatant from BCG stimulated RAW264.7 cells on bladder cancer cell line. 
Immunotherapy by BCG is approved by the FDA to treat, and prevent recurrence of high-risk 
superficial bladder cancer. In our study we could not detect any changes in the protein level 
of SK1 following SupBCG treatment. Our data provide no influence of SupBCG treatment 
alone on the levels of sphingolipid metabolites however cotreatment with SKI-II and 
SupBCG significantly increased the level of dihydro C16-ceramide. Treatment with SupBCG 
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or SKI-II individually induced PARP cleavage. Cotreatment with SupBCG and SKI-II has 
also shown increased cytotoxicity towards bladder cancer cell line. This study implies that 
targeting SKs adds to the cytotoxicity of BCG in bladder cancer cells. Further studies 
investigating autophagy and involvement of PI3K/ AKT pathway after the combined 
treatmentnarenrequired. 
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